Absence of Efficacy of Everolimus in Neurofibromatosis 1-Related Plexiform Neurofibromas: Results from a Phase 2a Trial
O. Zehou, P. Wolkenstein(Université Paris-Est Créteil), S. Barbarot(Hotel Dieu Hospital), É. Sbidian(Inserm), S. Ferkal(Lyon 1 Université), L. Valeyrie‐Allanore, P. Combemale(Centre Léon Bérard), Sylvie Bastuji‐Garin(Inserm), Pierre Brugières
Cited by 26
Related Papers
Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation
|Genetics in Medicine|2021|766
Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial
|The Lancet|2014|436
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
|The Lancet Oncology|2015|432
European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy
|Journal of the European Academy of Dermatology and Venereology|2022|419
European guideline (<scp>EuroGuiDerm</scp>) on atopic eczema – part <scp>II</scp>: non‐systemic treatments and treatment recommendations for special <scp>AE</scp> patient populations
|Journal of the European Academy of Dermatology and Venereology|2022|271